Neurocrine Biosciences (NBIX) Change in Inventory (2017 - 2026)

Neurocrine Biosciences (NBIX) has reported Change in Inventory for 10 consecutive years, with $6.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Inventory rose 409.52% year-over-year to $6.5 million; the trailing twelve-month figure through Jun 2026 stood at $17.9 million (up 23.45% YoY), and the FY2025 full-year result was $15.3 million, down 19.9% from the prior year.
• Change in Inventory improved to $6.5 million in Q2 2026 per NBIX's latest filing, from -$4.3 million in the prior quarter.
• Across five years, Change in Inventory topped out at $12.3 million in Q3 2025 and bottomed at -$4.3 million in Q1 2026.
• Historically, Change in Inventory has averaged $1.9 million across 5 years, with a median of $600000.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: Change in Inventory sank 633.33% in 2023, then surged 1188.89% in 2024.
• Over 5 years, Change in Inventory stood at -$3.9 million in 2022, then surged by 123.08% to $900000.0 in 2023, then soared by 1188.89% to $11.6 million in 2024, then plunged by 70.69% to $3.4 million in 2025, then surged by 91.18% to $6.5 million in 2026.
• According to Business Quant data, Change in Inventory over the past three periods registered $6.5 million, -$4.3 million, and $3.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.